Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A multicenter phase 2 trial of ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with combination chemotherapy with anti-EGFR antibody: JACCRO CC-16.
Authors
Masato Nakamura
Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan
Masato Nakamura , Akihito Tsuji , Yoshihiro Okita , Toshihiko Matsumoto , Tamotsu Sagawa , Takanori Watanabe , Kozo Kataoka , Dai Manaka , Kazuhiro Shiraishi , Naoya Akazawa , Tatsuya Okuno , Takaya Shimura , Manabu Shiozawa , Shingo Noura , Yu Sunakawa , Yasuki Akiyama , Hirofumi Ota , Masahiro Takeuchi , Wataru Ichikawa , Masashi Fujii
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
jRCTs061180002
DOI
10.1200/JCO.2022.40.4_suppl.112
Abstract #
112
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.
First Author: Atsushi Ishiguro
Poster
2021 Gastrointestinal Cancers Symposium
Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
First Author: Takanori Watanabe
Poster
2017 Gastrointestinal Cancers Symposium
A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT).
First Author: Masato Nakamura
Poster
2017 Gastrointestinal Cancers Symposium
A randomized phase II study to investigate the deepness of response (DpR) of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors: DEEPER.
First Author: Akihito Tsuji